AstraZeneca (AZN)

The latest reported fiscal year ended in December. Revenue increased from the preceding fiscal year, while operating profit grew faster and the operating margin widened. More of each sale remained after production, research and commercial costs.

Massive’s annual income statements also show higher net income and a wider profit margin. These are annual results; a recent quarterly result is not available in the financial evidence.

AstraZeneca sells branded medicines across major disease areas worldwide.

We like the combination of a cancer-led portfolio and a broad global reach. Its strongest opportunity is to build on that oncology foundation while developing medicines across other serious diseases. This is an exciting platform for turning sustained scientific investment into a stronger treatment portfolio.

Oncology is its largest therapeutic area, but the business also spans cardiovascular, renal and metabolic conditions, rare diseases, and respiratory and immunology treatments. Sales extend well beyond the United States, making international markets central to the business.

Revenue rose in the latest fiscal year, continuing the expansion visible in the annual history. The available figures do not separate that increase by medicine, therapeutic area, price or volume, so the consolidated growth cannot be attributed to oncology alone.

Research and development spending increased again. That investment is directly relevant to renewing a branded-medicine portfolio, but spending alone does not establish successful development. Specific research milestones and launch results are unavailable here.

Gross profit is revenue left after the reported cost of producing the medicines. It increased faster than revenue in the latest fiscal year, and the gross margin improved.

Selling, general and administrative expenses were broadly stable despite higher revenue. Research spending rose, but total operating expenses grew more slowly than sales. That cost pattern explains the wider operating margin without requiring a claim about any particular medicine.

Reported diluted earnings per share increased from the preceding fiscal year. The diluted share count was broadly stable, so the improvement reflected higher profit rather than a shrinking share base.

Net non-operating expenses declined, providing some additional support to earnings. The reported tax expense increased, however. Operating profit and shareholder earnings therefore improved together, but they remain distinct measures.

Massive’s annual cash-flow statements show higher cash generated by operations. Movements in operating assets and liabilities used cash, so that improvement did not depend on a favorable contribution from those movements.

Purchases of property, plant and equipment increased. Total investing cash outflow nevertheless declined because the reported other investing outflow was lower. The available statements do not identify the purposes of that other spending.

Operating cash covered total investing outflows and dividends in the latest fiscal year. Financing also included net debt repayments, and cash increased after all reported flows. This gives a more concrete picture of funding capacity than accounting profit alone.

The reported balance of current debt plus long-term debt and capital lease obligations declined from the preceding fiscal year. Cash increased and equity strengthened, although current debt rose as the longer-term balance fell.

Current liabilities still exceeded current assets. This means near-term obligations remain relevant even with stronger operating cash generation. Receivables and inventories also increased, tying more resources to customer payments and medicine stocks.

Goodwill and intangible assets remain prominent on the balance sheet. They are not cash available to settle obligations. Their carrying values are a material area to monitor if the economics of the underlying assets weaken.

The current analyst targets and SPY comparison are shown in Our verdict.

Watch whether AstraZeneca maintains its commercial cost discipline while continuing to fund research. Product-level sales and development milestones would help establish which parts of the portfolio are supporting growth.

Cash generation should remain a central checkpoint as spending on property, plant and equipment increases. Receivables, inventories, near-term obligations and the value of intangible assets are the clearest financial developments to follow.